FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337214501> ?p ?o ?g. }

• W2337214501 endingPage "7599" @default.
• W2337214501 startingPage "7599" @default.
• W2337214501 abstract "7599 Background: The cyclin-dependent kinase inhibitor flavopiridol is active in MCL and chronic lymphocytic leukemia (CLL) when given by 1-hr IV bolus dosing. Flavopiridol induces apoptosis independent of p53 and may eliminate tumor cells resistant to fludarabine and rituximab. Methods: We performed a phase I dose escalation study of flavopiridol, fludarabine and rituximab (FFR) in patients (pts) with MCL, CLL and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pts received fludarabine 25 mg/m 2 IV day 1–5 and rituximab 375 mg/m 2 day 1 every 28 days for up to 6 cycles. Flavopiridol was given 50 mg/m 2 by 1-hr IV bolus day 1 (cohort 1), day 1–2 (cohort 2), or day 1–3 (cohort 3) of each cycle. Growth factor support was prohibited. Results: Twenty-one pts were enrolled and are evaluable for toxicity and response. Median age was 62 years (range, 43–81); 8 pts had CLL, 5 MCL, 4 follicular NHL (FL), and 4 other low-grade NHL. Nine pts had received 1–2 prior therapies; 12 pts were previously untreated. CLL pts were Rai stage III/IV (5) or required treatment for stage I/II disease (3). NHL pts had stage III/IV (10) or progressive stage II disease (3). Dose limiting toxicity (DLT) was not observed in 3 pts in cohort 1. Two of 6 pts in cohort 2 developed DLT (grade 3 seizures; grade 3 renal failure due to nausea and diarrhea). Twelve additional pts were enrolled at the cohort 1 dose level, to define toxicity and efficacy. Pts received a median of 4 cycles (range 1–6), and 9 of 21 pts completed 6 cycles. Therapy was stopped early due to cytopenias (7), infection (2), DLT (2) or progressive disease (1). Response was graded by NCI 96 (CLL) or IWG (NHL) criteria. Overall response rate was 90%, and 14 pts achieved CR (67%). Six pts relapsed a median of 7.5 months (range 4–18) after finishing therapy; 13 pts remain in remission a median of 13.5 months (range 4–25) after therapy. All 9 MCL/FL pts responded (8 CR, 1 PR), and 8 pts remain in remission a median of 17 months (range 6–25) after therapy. Conclusions: FFR showed significant clinical activity in a small group of pts, but cytopenias limited therapy. We are currently studying a modified FFR regimen using a more active flavopiridol schedule (30-min IV bolus followed by 4-hr IV infusion) and allowing the use of prophylactic filgrastim. [Table: see text]" @default.
• W2337214501 created "2016-06-24" @default.
• W2337214501 creator A5000921376 @default.
• W2337214501 creator A5007739590 @default.
• W2337214501 creator A5009630384 @default.
• W2337214501 creator A5024835062 @default.
• W2337214501 creator A5025283014 @default.
• W2337214501 creator A5041950455 @default.
• W2337214501 creator A5055021281 @default.
• W2337214501 creator A5056697792 @default.
• W2337214501 creator A5063328750 @default.
• W2337214501 creator A5065968907 @default.
• W2337214501 creator A5070672137 @default.
• W2337214501 date "2006-06-20" @default.
• W2337214501 modified "2023-09-27" @default.
• W2337214501 title "Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL)" @default.
• W2337214501 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.7599" @default.
• W2337214501 hasPublicationYear "2006" @default.
• W2337214501 type Work @default.
• W2337214501 sameAs 2337214501 @default.
• W2337214501 citedByCount "3" @default.
• W2337214501 crossrefType "journal-article" @default.
• W2337214501 hasAuthorship W2337214501A5000921376 @default.
• W2337214501 hasAuthorship W2337214501A5007739590 @default.
• W2337214501 hasAuthorship W2337214501A5009630384 @default.
• W2337214501 hasAuthorship W2337214501A5024835062 @default.
• W2337214501 hasAuthorship W2337214501A5025283014 @default.
• W2337214501 hasAuthorship W2337214501A5041950455 @default.
• W2337214501 hasAuthorship W2337214501A5055021281 @default.
• W2337214501 hasAuthorship W2337214501A5056697792 @default.
• W2337214501 hasAuthorship W2337214501A5063328750 @default.
• W2337214501 hasAuthorship W2337214501A5065968907 @default.
• W2337214501 hasAuthorship W2337214501A5070672137 @default.
• W2337214501 hasConcept C126322002 @default.
• W2337214501 hasConcept C141071460 @default.
• W2337214501 hasConcept C143998085 @default.
• W2337214501 hasConcept C2776694085 @default.
• W2337214501 hasConcept C2776755627 @default.
• W2337214501 hasConcept C2777058707 @default.
• W2337214501 hasConcept C2777525834 @default.
• W2337214501 hasConcept C2777938653 @default.
• W2337214501 hasConcept C2778461978 @default.
• W2337214501 hasConcept C2778822529 @default.
• W2337214501 hasConcept C2779263901 @default.
• W2337214501 hasConcept C2779338263 @default.
• W2337214501 hasConcept C2779709957 @default.
• W2337214501 hasConcept C2780653079 @default.
• W2337214501 hasConcept C2781442060 @default.
• W2337214501 hasConcept C71924100 @default.
• W2337214501 hasConcept C72563966 @default.
• W2337214501 hasConcept C90924648 @default.
• W2337214501 hasConceptScore W2337214501C126322002 @default.
• W2337214501 hasConceptScore W2337214501C141071460 @default.
• W2337214501 hasConceptScore W2337214501C143998085 @default.
• W2337214501 hasConceptScore W2337214501C2776694085 @default.
• W2337214501 hasConceptScore W2337214501C2776755627 @default.
• W2337214501 hasConceptScore W2337214501C2777058707 @default.
• W2337214501 hasConceptScore W2337214501C2777525834 @default.
• W2337214501 hasConceptScore W2337214501C2777938653 @default.
• W2337214501 hasConceptScore W2337214501C2778461978 @default.
• W2337214501 hasConceptScore W2337214501C2778822529 @default.
• W2337214501 hasConceptScore W2337214501C2779263901 @default.
• W2337214501 hasConceptScore W2337214501C2779338263 @default.
• W2337214501 hasConceptScore W2337214501C2779709957 @default.
• W2337214501 hasConceptScore W2337214501C2780653079 @default.
• W2337214501 hasConceptScore W2337214501C2781442060 @default.
• W2337214501 hasConceptScore W2337214501C71924100 @default.
• W2337214501 hasConceptScore W2337214501C72563966 @default.
• W2337214501 hasConceptScore W2337214501C90924648 @default.
• W2337214501 hasIssue "18_suppl" @default.
• W2337214501 hasLocation W23372145011 @default.
• W2337214501 hasOpenAccess W2337214501 @default.
• W2337214501 hasPrimaryLocation W23372145011 @default.
• W2337214501 hasRelatedWork W1867956999 @default.
• W2337214501 hasRelatedWork W2105172500 @default.
• W2337214501 hasRelatedWork W2127507395 @default.
• W2337214501 hasRelatedWork W2132818131 @default.
• W2337214501 hasRelatedWork W2336105736 @default.
• W2337214501 hasRelatedWork W2549455426 @default.
• W2337214501 hasRelatedWork W2994251693 @default.
• W2337214501 hasRelatedWork W4205929773 @default.
• W2337214501 hasRelatedWork W4250692607 @default.
• W2337214501 hasRelatedWork W104003552 @default.
• W2337214501 hasVolume "24" @default.
• W2337214501 isParatext "false" @default.
• W2337214501 isRetracted "false" @default.
• W2337214501 magId "2337214501" @default.
• W2337214501 workType "article" @default.